CA
TPTX

Corriente Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Corriente Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-285,000
Closed -$17.8M – 21
2019
Q4 		$17.8M Buy
+285,000
New +$13.6M 9.54% 5

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Corriente Advisors's TPTX Position: Q1 2020 in Review

Corriente Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2020, closing a stake of 285,000 shares — an estimated $17.8M sold.

Corriente Advisors first reported a position in TPTX in Q4 2019 and held it in 1 quarter. The position peaked at $17.8M in Q4 2019. 119 funds tracked by Wall St. Rank hold TPTX as of Q1 2020.

  • Corriente Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Corriente Advisors sold 285,000 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $17.8M.
  • Corriente Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Corriente Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $17.8M in Q4 2019.
  • 119 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Corriente Advisors's 13F filing for Q1 2020, filed 18 May 2020.